OGEN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OGEN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Oragenics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0. Oragenics's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.
As of today (2025-03-04), Oragenics's share price is $0.2699. Oragenics's Median PS Value is $0.00. Therefore, Oragenics's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Oragenics's Median PS Value or its related term are showing as below:
The historical data trend for Oragenics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oragenics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Median PS Value | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Oragenics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Median PS Value | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Oragenics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Oragenics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Oragenics's Price-to-Median-PS-Value falls into.
Oragenics's Median PS Value for today is calculated as
Median PS Value | = | Revenue per Share (TTM) | * | 10-Year Median PS Ratio |
= | 0 | * | ||
= | 0.00 |
10-Year Median PS Ratio is .
Oragenics's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oragenics (AMEX:OGEN) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Oragenics's Price to Median PS Value for today is calculated as
Price to Median PS Value | = | Share Price | / | Median PS Value |
= | 0.2699 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Oragenics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Alan W Dunton | director | VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406 |
Fred Telling | director | 501 ELLIOTT AVE. W., SUITE 400, SEATTLE WA 98119 |
John P Gandolfo | director | 62 TERRACE ROAD, WAYNE NJ 07470 |
Cassidy Bruce A. Sr. | director | C/O LOOP MEDIA, 700 N CENTRAL AVENUE, SUITE 430, GLENDALE CA 91203 |
Janet Huffman | officer: CFO, Secretary and Treasurer | 5317 FRUITVILLE RD SUITE 6, SARASOTA FL 34232 |
Robert C Koski | director, 10 percent owner | 1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243 |
Michael O'keefe Sullivan | officer: CFO, Secretary and Treasurer | 3000 BAYPORT DRIVE, SUITE 685, TAMPA FL 33607 |
Joseph Hernandez | 10 percent owner | C/O MICROLIN BIO, INC., NEW YORK NY 10022 |
Kimberly M Murphy | director | 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602 |
Koski Family Lp | 10 percent owner | 1500 W UNIVERSITY PARKWAY, SARASOTA FL 34243 |
Randal J Kirk | 10 percent owner | 1881 GROVE AVENUE, RADFORD VA 24141 |
Alan Joslyn | director, officer: CEO and President | 39 OLD RIDGEBURY ROAD, DANBURY CT 06810 |
Charles L Pope | director | 4902 EISENHOWER BOULEVARD, TAMPA FL 33634 |
Christine L Koski | director, 10 percent owner | 1500 WEST UNIVERSITY PARKWAY, SARASOTA FL 34243 |
Thomas L Koski | 10 percent owner |
From GuruFocus
By PRNewswire PRNewswire • 07-22-2020
By PRNewswire PRNewswire • 05-19-2020
By GuruFocus Research GuruFocus Editor • 01-14-2022
By PRNewswire PRNewswire • 01-04-2022
By PRNewswire PRNewswire • 10-04-2018
By PRNewswire PRNewswire • 07-10-2020
By PRNewswire PRNewswire • 12-20-2021
By PRNewswire PRNewswire • 08-20-2020
By Marketwired Marketwired • 06-20-2018
By PRNewswire PRNewswire • 10-06-2020
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.